Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients

Exelixis gambled a little more than a year ago, deciding to go “all-in” on its lead drug candidate for cancer after many investors lost interest in its strategy of building a broad pipeline with lots of different drugs.
Xconomy